Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

Journal:

Nature Communications

Published:

2026-05-16

DOI:

10.1038/s41467-026-73085-1

Affiliations:

22

Authors:

44

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	11.250000 11.250000	0.26
Harvard Medical School (HMS), United States of America (USA)	8.416667	0.19
Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), United States of America (USA)	7.583333	0.17
Broad Institute of MIT and Harvard, United States of America (USA)	3.583333	0.08
Foundation Medicine, Inc., United States of America (USA)	3.000000	0.07
4D Path Inc., United States of America (USA)	2.000000	0.05
Harvard University, United States of America (USA)	1.000000	0.02
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA)	1.000000	0.02
Eastern Maine Medical Center (EMMC), United States of America (USA)	1.000000	0.02
Stamford Hospital - Bennett Medical Center, United States of America (USA)	1.000000	0.02
Medical Center, UVM, United States of America (USA)	1.000000	0.02
UMass Memorial Medical Center, United States of America (USA)	1.000000	0.02
Biovica, United States of America (USA)	1.000000	0.02
Brigham and Women's Hospital (BWH), United States of America (USA)	0.666667	0.02
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	0.500000	0.01

Interested in Oncology and Carcinogenesis?